Secretory activity of the coronary artery endothelial cells in conditions of the peritoneal dialysis.
Adult
Anticoagulants
/ pharmacology
Coronary Vessels
/ cytology
Dialysis Solutions
/ adverse effects
Endothelial Cells
/ metabolism
Female
Glycosaminoglycans
/ pharmacology
Humans
Interleukin-6
/ metabolism
Male
Middle Aged
Peritoneal Dialysis, Continuous Ambulatory
/ methods
Plasminogen Activator Inhibitor 1
/ metabolism
Tissue Plasminogen Activator
/ metabolism
von Willebrand Factor
/ metabolism
Peritoneal dialysis
Sulodexide
coronary endothelium
inflammation
Journal
Renal failure
ISSN: 1525-6049
Titre abrégé: Ren Fail
Pays: England
ID NLM: 8701128
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
entrez:
17
2
2022
pubmed:
18
2
2022
medline:
8
3
2022
Statut:
ppublish
Résumé
Endothelial dysfunction is frequent in patients treated with peritoneal dialysis and may lead to cardiac complications. We evaluated the effect of effluent dialysates and serum on the function of coronary artery endothelial cells (CAEC). Human CAEC in Serum from CAPD patients stimulated synthesis of IL6 (+93%), vWF (+18%), and PAI-1 (+20%) and did not change t-PA secretion in CAEC. Dialysates stimulated secretion of IL6 (+89%), vWF (+29%), and PAI-1 (+31%) and did not change t-PA synthesis. Dialysates collected in 12 patients after 6 months more strongly stimulated synthesis of IL6 (+37%) and PAI-1 (+7%). Sulodexide suppressed the secretory activity of CAEC stimulated by the studied sera: IL6 (-38%), vWF (-19%), t-PA (-13%), and PAI-1 (-12%). Serum and the dialysate from CAPD patients induce inflammatory and prothrombotic reaction in coronary arterial endothelial cells. The general pattern of the observed effects for serum and dialysates was similar but the intensity of the effects was not identical. Sulodexide reduced these effects.
Identifiants
pubmed: 35174782
doi: 10.1080/0886022X.2021.2023024
pmc: PMC8856042
doi:
Substances chimiques
Anticoagulants
0
Dialysis Solutions
0
Glycosaminoglycans
0
Interleukin-6
0
Plasminogen Activator Inhibitor 1
0
von Willebrand Factor
0
glucuronyl glucosamine glycan sulfate
75HGV0062C
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
54-61Références
Cell Physiol Biochem. 2016;40(5):1005-1012
pubmed: 27941341
Perit Dial Int. 1997 Mar-Apr;17(2):157-61
pubmed: 9159836
Clin J Am Soc Nephrol. 2010 Feb;5(2):227-34
pubmed: 20056757
Nephrol Dial Transplant. 2003 Jul;18(7):1370-5
pubmed: 12808175
Nephrol Dial Transplant. 2012 Mar;27(3):1191-9
pubmed: 21862454
Medicine (Baltimore). 2014 Sep;93(11):e73
pubmed: 25192486
Clin Invest Med. 2016 Sep 11;39(4):E111-9
pubmed: 27619398
Perit Dial Int. 2013 Mar-Apr;33(2):208-12
pubmed: 23478374
Hemodial Int. 2014 Jul;18(3):650-6
pubmed: 24612443
Int Angiol. 2016 Apr;35(2):140-7
pubmed: 26868135
J Am Soc Nephrol. 2012 Nov;23(11):1900-8
pubmed: 23085635
J Thromb Haemost. 2019 Jan;17(1):31-38
pubmed: 30394690
Kidney Int. 1999 May;55(5):1952-60
pubmed: 10231459
Perit Dial Int. 2012 Mar-Apr;32(2):149-58
pubmed: 20864603
Kidney Int. 2000 Mar;57(3):1182-9
pubmed: 10720971
J Physiol Pharmacol. 2019 Dec;70(6):
pubmed: 32203941
BMC Nephrol. 2014 Jan 10;15:8
pubmed: 24410736
Nephrol Dial Transplant. 2010 Apr;25(4):1266-71
pubmed: 19926717
Cardiol Rev. 2014 May-Jun;22(3):147-51
pubmed: 24618929
Pediatr Nephrol. 1990 Mar;4(2):152-5
pubmed: 2397181
Perit Dial Int. 2014 Nov-Dec;34(7):706-13
pubmed: 24584618
Ren Fail. 2021 Dec;43(1):401-405
pubmed: 33641611
J Cell Mol Med. 2017 Nov;21(11):2720-2731
pubmed: 28444875
Int Angiol. 2014 Jun;33(3):229-35
pubmed: 24936531
Perit Dial Int. 2003 Jul-Aug;23(4):381-90
pubmed: 12968847
Perit Dial Int. 2007 Jul-Aug;27(4):456-60
pubmed: 17602156
Am J Kidney Dis. 1996 Jun;27(6):848-54
pubmed: 8651250
Kidney Blood Press Res. 2019;44(2):277-285
pubmed: 30959503
PLoS One. 2012;7(2):e30975
pubmed: 22383985
Cardiorenal Med. 2017 Feb;7(2):104-117
pubmed: 28611784
Blood Purif. 2014;38(1):7-12
pubmed: 25196796
Blood Purif. 2007;25(5-6):510-4
pubmed: 18187942